

Botulinum Neurotoxin Serotype F: Identification of Substrate Recognition Requirements and Development of Inhibitors with Low Nanomolar Affinity

James J. Schmidt* and Robert G. Stafford

Toxinology Division, United States Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Fort Detrick, Maryland 21702

Received October 19, 2004; Revised Manuscript Received January 6, 2005

ABSTRACT: Botulinum neurotoxins (BoNTs A–G) are zinc metalloendoproteases that exhibit extraordinary specificities for proteins involved in neurotransmitter release. In view of the extreme toxicities of these molecules, their applications in human medicine, and potential for misuse, it is of considerable importance to elucidate the mechanisms underlying substrate recognition and to develop inhibitors, with the ultimate goal of obtaining anti-botulinum drugs. We synthesized peptides based on vesicle-associated membrane protein (VAMP) to investigate the substrate requirements of BoNT F, which cleaves VAMP between residues Q58 and K59. The minimum substrate was a peptide containing VAMP residues 32–65, which includes only one of the two VAMP structural motifs thought to be required for botulinum substrate recognition. BoNT F exhibited a strict requirement for residues D57 (P₂), K59 (P₁'), and L60 (P₂'), but peptides containing substitutions for R56 (P₃), Q58 (P₁), and S61 (P₃') were cleaved. Therefore, the P₂, P₁', and P₂' residues of VAMP are of paramount importance for BoNT F substrate recognition near the scissile bond. K_i values of uncleavable analogues were similar to K_m values of the substrate, suggesting that substrate discrimination occurs at the cleavage step, not at the initial binding step. We then synthesized inhibitors of BoNT F that incorporated D-cysteine in place of glutamine 58, exhibited K_i values of 1–2 nM, and required binding groups on the N-terminal but not the C-terminal side of the zinc ligand. The latter characteristic distinguishes BoNT F from other zinc metalloendoproteases, including BoNTs A and B.

The clostridial neurotoxins consist of tetanus toxin, secreted by *Clostridium tetani*, and the seven serologically distinct botulinum toxins, designated types A–G, produced by various strains of *Clostridium botulinum*, *Clostridium baratii*, and *Clostridium butyricum* (1–3). They are the most toxic substances known (4). Each neurotoxin is synthesized as a single-chain protein with an *M_r* of ~150 000. Endogenous proteases then act to produce the dichain structure, consisting of an *M_r* ~ 100 000 heavy chain and an *M_r* ~ 50 000 light chain, covalently linked by a disulfide bond. The dichain is thought to be the active form of the toxin (1). In the United States, there are ~200 cases of human botulism each year, due to ingestion of toxin-contaminated food, wound infections, or colonization of the intestinal tract by *C. botulinum* (5–7). However, much of the current interest in BoNTs¹ stems from their use as tools in research on the mechanisms of neurotransmission (1, 8, 9), an ever-expanding number of applications in the treatment of human muscle dysfunctions (10–13), and their potential for use as bioterrorist weapons (14).

Intoxication resulting in the flaccid paralysis of botulism or the spastic paralysis of tetanus has been described as a

four-step process, consisting of (1) toxin binding to specific receptors on neurons, (2) receptor-mediated toxin endocytosis, (3) translocation through the endosomal membrane, and (4) proteolytic inactivation of neuronal proteins critical to the mechanism of neurotransmitter release. The first three steps are mediated by the heavy chain, while the fourth is effected by the zinc metalloprotease activity of the light chain (15, 16). In the development of improved treatments for clostridial neurotoxin poisoning, each of the steps represents a potential target for therapeutic intervention. However, use of drugs directed against any of the first three (17–20) requires an awareness of toxin exposure before symptoms appear, which is seldom the case. In contrast, drugs based on inhibitors that inactivate toxin metalloprotease activity could be effective at any stage of disease progression. Such inhibitors must exhibit strong binding characteristics (K_i values in the low nanomolar range, or better) and a high degree of specificity for clostridial neurotoxin(s) and must include an intracellular delivery mechanism for acute-stage therapy. With respect to the first two qualifications, previously identified inhibitors of other metalloproteases had only weak effects on BoNT and tetanus activities (21–23), while zinc chelators were too toxic and nonspecific for in vivo use (24).

Development of effective BoNT or TeNT inhibitors must be based on an understanding of the extraordinary substrate specificities exhibited by the clostridial neurotoxins. Each cleaves only a single bond in its neuronal target protein:

* To whom correspondence should be addressed. Phone: (301) 619-4240. Fax: (301) 619-2348. E-mail: james.schmidt@det.amedd.army.mil.

¹ Abbreviations: BoNT, botulinum neurotoxin; HPLC, high-pressure liquid chromatography; SNAP-25, synaptosomal-associated protein with an *M_r* of 25 000; SNARE, soluble N-ethylmaleimide-sensitive factor accessory protein receptor; TeNT, tetanus neurotoxin; VAMP, vesicle-associated membrane protein.

Report Documentation Page				Form Approved OMB No. 0704-0188	
Public reporting burden for the collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to a penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number.					
1. REPORT DATE 02 FEB 2005		2. REPORT TYPE N/A		3. DATES COVERED -	
4. TITLE AND SUBTITLE Botulinum neurotoxin serotype F: identification of substrate recognition requirements and development of inhibitors with low nanomolar affinity, Biochemistry 44:4067 - 4073				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Schmidt, JJ Stafford, RG				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD				8. PERFORMING ORGANIZATION REPORT NUMBER RPP-04-369	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES)				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION/AVAILABILITY STATEMENT Approved for public release, distribution unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Botulinum neurotoxins (BoNTs A-G) are zinc metalloendoproteases that exhibit extraordinary specificities for proteins involved in neurotransmitter release. In view of the extreme toxicities of these molecules, their applications in human medicine, and potential for misuse, it is of considerable importance to elucidate the mechanisms underlying substrate recognition and to develop inhibitors, with the ultimate goal of obtaining anti-botulinum drugs. We synthesized peptides based on vesicle-associated membrane protein (VAMP) to investigate the substrate requirements of BoNT F, which cleaves VAMP between residues Q58 and K59. The minimum substrate was a peptide containing VAMP residues 32 - 65, which includes only one of the two VAMP structural motifs thought to be required for botulinum substrate recognition. BoNT F exhibited a strict requirement for residues D57 (P2), K59 (P1'), and L60 (P2'), but peptides containing substitutions for R56 (P3), Q58 (P1), and S61 (P3') were cleaved. Therefore, the P2, P1', and P2' residues of VAMP are of paramount importance for BoNT F substrate recognition near the scissile bond. Ki values of uncleavable analogs were similar to Km of the substrate, suggesting that substrate discrimination occurs at the cleavage step, not at the initial binding step. We then synthesized inhibitors of BoNT F that incorporated D-cysteine in place of glutamine-58, exhibited Ki values of 1 - 2 nM, and required binding groups on the N-terminal but not the C-terminal side of the zinc ligand. The latter characteristic distinguishes BoNT F from other zinc metalloendoproteases, including BoNTs A and B.					
15. SUBJECT TERMS Clostridium botulinum, neurotoxin, type F, substrate specificity, inhibitor, protease					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT SAR	18. NUMBER OF PAGES 7	19a. NAME OF RESPONSIBLE PERSON
a. REPORT unclassified	b. ABSTRACT unclassified	c. THIS PAGE unclassified			

17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35
G	G	P	P	A	P	P	P	N	L	T	S	N	R	R	L	Q	Q	T
36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54
Q	A	Q	<u>V</u>	<u>D</u>	<u>E</u>	<u>V</u>	<u>V</u>	<u>D</u>	<u>I</u>	<u>M</u>	<u>R</u>	<u>V</u>	N	V	D	K	V	L
55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73
E	R	D	Q	K	L	S	E	<u>L</u>	<u>D</u>	<u>D</u>	<u>R</u>	<u>A</u>	<u>D</u>	<u>A</u>	<u>L</u>	<u>Q</u>	A	G
	P ₃	P ₂	P ₁	P ₁ '	P ₂ '	P ₃ '												
74	75	76	77	78	79	80	81	82	83	84	85	86						
A	S	Q	F	E	T	S	A	A	K	L	K	R						

FIGURE 1: Partial amino acid sequence of human VAMP-2, showing residues included in peptides described in this report. The BoNT F cleavage site is highlighted in bold, and SNARE motifs (26, 27) are underlined.

BoNTs A, C, and E cleave SNAP-25, while BoNTs B, D, F, and G and TeNT cleave VAMP (synaptobrevin). BoNT C also cleaves syntaxin (1, 10, 12, 25). Because identical bonds occur at multiple sites in the neuronal proteins and in many other proteins as well, substrate recognition must include sequences and structures both adjacent to and at some distance from the cleavage sites. In this regard, short helical segments called SNARE motifs have been identified in all three neuronal target proteins, and are said to be required for substrate recognition and cleavage (26, 27). Nevertheless, several BoNT serotypes and tetanus toxin were shown to cleave synthetic peptides, and these developments led to convenient HPLC-based assays (28–31) and to high-throughput assay systems (32–34) which have proven to be invaluable in the development of specific, high-affinity inhibitors of BoNT A (35–38), BoNT B (39–43), and TeNT (44, 45). This approach is not invalidated by the possibility that substrate segments absent from the synthetic peptides might influence kinetics, because K_i is independent of the substrate that was used to determine it.

Because of the extensive and unique BoNT substrate requirements, it is unlikely that a specific BoNT inhibitor will be highly effective against more than one serotype. Those that are multiserotype inhibitors might also inhibit other metalloproteases, an undesirable side effect. Therefore, detailed studies on the enzymatic characteristics of each BoNT serotype are needed. In this context, we have investigated the catalytic properties of BoNT F, identified its substrate requirements near the scissile bond, uncovered significant similarities and differences with respect to other serotypes, and developed specific inhibitors that bind to BoNT F with extremely high affinity. The latter exhibited a requirement for binding moieties on the N-terminal but not the C-terminal side of the zinc ligand, a highly unusual feature among metalloendoproteases.

MATERIALS AND METHODS

Peptide Synthesis. The peptide synthesizer was a model 431A system from Applied Biosystems (Foster City, CA). All peptides were C-terminal amides, and N-terminal amino groups were acetylated. Peptides were purified by reverse-phase HPLC with gradients of dilute trifluoroacetic acid and acetonitrile using equipment from Waters Associates (Milford, MA). To confirm that the appropriate fractions had been collected, purified peptides were subjected to mass spectrometry and results were compared to calculated values.

BoNT F Protease Assays. BoNT F was obtained from Metabio (Madison, WI). Toxin protease activity was preactivated by incubation in 20 mM HEPES, 0.05% Tween 20, 10 mM dithiothreitol, and 0.5 mM ZnCl₂ (pH 7.3) at 37 °C for 30 min. It was then divided into small aliquots and stored at –70 °C. Assay mixtures contained 2 mM dithiothreitol, 80 μM ZnCl₂, 1.5 μg/mL BoNT F (approximately 10 nM), 20 mM HEPES, and 0.05% Tween 20 (pH 7.3). Inclusion of Tween in assays led to a small (~5–10%) but reproducible increase in BoNT F activity and improved reproducibility. As found for BoNT A (30), optimum BoNT F protease activity required addition of both dithiothreitol and zinc to assays. But unlike BoNT A assays (31), bovine serum albumin was not included because it had no effect on BoNT F protease activity. The samples were incubated at 37 °C for various times, depending on substrate and inhibitor concentrations, so that less than 10% of the substrate was hydrolyzed. Assays were stopped by acidification with trifluoroacetic acid and analyzed by HPLC (30, 31).

Data Analysis. Kinetic constants were calculated from nonlinear regression plots with Enzfitter (Biosoft, Cambridge, United Kingdom), including at least seven different substrate concentrations. K_i values were calculated from slopes of Dixon plots using the equation $K_i = K_m / [(slope) V_{max} S]$, where S is the substrate concentration (46). Because each inhibitor differed from the corresponding substrate peptide by only one residue, we assumed that inhibition was competitive. In the tables, each value is the average of three independent experiments. Standard deviations (not shown) were less than 20% in all cases.

RESULTS

Peptide Substrates for BoNT F Protease Activity. In earlier work, we reported that BoNT F could cleave a relatively short synthetic peptide consisting of VAMP residues 37–75 (33). BoNT F cleaved peptide 37–75 between Q58 and K59, the same site as in whole VAMP. In this work, we determined kinetic constants for this peptide when hydrolyzed by BoNT F, and then modified it to determine BoNT F substrate requirements near the cleavage site. The partial amino acid sequence of human VAMP 2, encompassing peptides described in this work, is shown in Figure 1.

Kinetic Constants of BoNT F Peptide Substrates. The effects of variable substrate length on kinetic constants are summarized in Table 1. Values for peptide 37–75 are similar to those reported for a 17-residue BoNT A substrate (31).

Table 1: Kinetic Constants of BoNT F Peptide Substrates

VAMP residues	relative rate ^a	K_m (mM)	V_{max} ($\mu\text{mol min}^{-1} \text{mg}^{-1}$)
42–75	0.0		
37–75	1.0	1.1	6.7
37–86	0.71	0.61	3.3
32–75	5.3	0.53	23
27–75	6.9	0.29	23
32–65	6.8	0.31	23

^a With 0.5 mM substrate.

However, truncating five residues on the N-terminal side to yield peptide 42–75 eliminated BoNT F-catalyzed hydrolysis, clearly demonstrating that one or more residues of peptide 37–41 are required by BoNT F for substrate binding and/or catalysis.

Extending the peptide on the C-terminal side by 11 more VAMP residues to obtain peptide 37–86 did not yield a more efficient substrate. Compared to those of peptide 37–75, the K_m was lower but V_{max} was also reduced, emphasizing the fact that binding and catalysis are distinct events that can be independently influenced by substrate structural changes. Substrates that bind more tightly are not necessarily cleaved more rapidly. We concluded that VAMP residues 76–86 are not critical for substrate recognition by BoNT F.

In contrast, adding five N-terminal residues to give peptide 32–75 resulted in significantly lower K_m and higher maximum velocity values, compared to those of peptide 37–75. This additional sequence is well outside any of the SNARE motifs in VAMP. Nonetheless, it was clear that one or more of VAMP residues 32–36 are important for substrate binding and catalysis by BoNT F. Within this five-residue segment, we then synthesized and tested substrates, adding amino acids one at a time to the N-terminus of peptide 37–75. The effect on kinetic constants was cumulative, indicating that no individual residue was predominantly responsible for the changes (data not shown). In this region, we have not yet examined the consequences of residue substitutions on substrate properties.

Further extension of the substrate on the N-terminal side had only small effects. Peptide 27–75 had a slightly lower K_m , compared to that of peptide 32–75, but its V_{max} was identical.

Finally, the effect of substrate truncation on the C-terminal side of the scissile bond was tested with substrate peptide 32–65. This change eliminated most of the residues in the second SNARE motif. Nonetheless, V_{max} was unchanged, compared to that of peptide 32–75, and its K_m was very similar. Both values were identical to those of peptide 27–75. Therefore, VAMP residues 66–75 are not required for substrate recognition and cleavage by BoNT F.

Hydrolysis of Substrate Analogues. Peptides were synthesized to test the effects of amino acid substitutions on the kinetic properties of the substrate. Residues were changed, one per peptide, in a segment from R56 (P_3 with respect to the cleavage site) to S61 (P_3'). In certain cases, peptides that were not cleaved by BoNT F were tested as inhibitors. Results are presented in Table 2.

Substituting alanine for arginine at P_3 (R56A) greatly reduced but did not eliminate hydrolysis. Therefore, the side chain of arginine is preferred but not required by BoNT F at this location. In contrast, substrate analogues containing

Table 2: Effects of Single-Amino Acid Substitutions on Kinetic Constants

VAMP 37–75 substitution	relative rate ^a	K_m or K_i (mM)	V_{max} ($\mu\text{mol min}^{-1} \text{mg}^{-1}$)
none	1.0	1.1	6.7
R56A	0.10	ND ^b	ND ^b
D57E	0.0	0.83	
D57N	0.0	1.8	
D57A	0.0	0.47	
Q58N	0.69	0.92	4.1
Q58A	0.27	1.8	2.6
K59R	0.0	3.5	
K59A	0.0	0.17	
L60A	0.0	ND ^b	
S61A	1.3	0.89	7.5

^a With 0.5 mM substrate. ^b Not determined.Table 3: K_i Values of Cysteine-Containing BoNT F Inhibitors

VAMP residues	substitution	K_i (μM)
37–75	Q58C	78
37–75	Q58D-C	7.2
58–75	Q58C	> 500
58–75	Q58D-C	> 500
37–58	Q58C	11
37–58	Q58D-C	0.28

conservative replacements for aspartic acid at P_2 were not cleaved by BoNT F. These replacements included lengthening the side chain by one methylene group (D57E), eliminating the negative charge (D57N), or eliminating the carboxyl group (D57A). When P_2 -substituted peptides were tested as inhibitors, their K_i values were similar to the K_m of the native sequence substrate, indicating that these peptides bound to BoNT F, but the complexes did not proceed to the catalytic stage.

Changes to glutamine at P_1 (Q58N and Q58A) did not eliminate BoNT F-catalyzed hydrolysis, but peptides containing arginine or alanine in place of the native sequence lysine at P_1' were not cleaved. Testing the latter two analogues as inhibitors revealed a pattern similar to that seen for the P_2 -substituted peptides, in that binding was not strongly affected but cleavage did not occur. Finally, substituting alanine for leucine (P_2') eliminated BoNT F-catalyzed hydrolysis, but replacing serine at P_3' with alanine had no substantial effect.

Substrate-Based Inhibitors of BoNT F Protease Activity. Results from our earlier work with BoNT A and BoNT B inhibitors (34–36) suggested that introducing a zinc-binding moiety, the sulfhydryl group, near the scissile bond in peptide 37–75 would inhibit BoNT F protease activity. Therefore, analogues of substrate peptide 37–75 were synthesized with L- or D-cysteine substituted for glutamine at P_1 or lysine at P_1' . Peptides with L- or D-cysteine at P_1' were not cleaved by BoNT F but were weak inhibitors ($K_i \geq 0.1$ mM; data not shown). However, peptides containing L- or D-cysteine at P_1 were effective inhibitors (Table 3), with the D-cysteine peptide exhibiting a 10-fold higher affinity than the L-isomer. We then synthesized truncated versions, to determine contributions of the other residues to binding. Eliminating amino acids 37–57 (peptides 58–75/Q58C and 58–75/Q58D-C) abolished inhibition. In contrast, eliminating residues 59–75 on the C-terminal side of cysteine significantly enhanced binding affinity. Again, the D-cysteine inhibitor, 37–58/Q58D-C, was more effective, with a K_i of 0.28 μM ,

Table 4: K_i Values of BoNT F Inhibitors with a C-Terminal Q58D-C Mutation

VAMP residues	K_i (nM)	VAMP residues	K_i (nM)
42–58	9000	27–58	1.9
37–58	280	22–58	1.0
32–58	34	17–58	1.3

compared to a value of 11 μ M for the peptide containing the L-isomer.

High-Affinity Inhibitors of BoNT F Protease Activity. A series of inhibitors was then synthesized, each with C-terminal D-cysteine in place of the native sequence glutamine, to test the effect of N-terminal chain length on binding affinity. Results are shown in Table 4. Eliminating residues 37–41 (peptide 42–58/Q58D-C) drastically inhibited binding, reflecting the previously described importance of these residues for substrate function. In contrast, extending the peptide toward the N-terminus of VAMP substantially strengthened inhibitor binding, compared to that of peptide 37–58/Q58D-C. Adding five residues (32–58/Q58D-C) yielded an 8-fold decrease in K_i , while another five (27–58/Q58D-C) yielded a further 17-fold decrease. A small but reproducible improvement was obtained by adding residues 22–26, while including residues 17–21 had no effect. In sum, highly potent inhibitors of BoNT F protease activity with K_i values in the 1–2 nM range were obtained, based on VAMP residues 22–58, with D-cysteine in place of glutamine 58. The latter corresponds to the P_1 residue of the substrate.

Binding constants for the most effective inhibitors were calculated from experiments where inhibitor concentrations were close to that of BoNT F (Table 4). Therefore, the free inhibitor concentration could have been lower than its calculated value because a significant fraction was bound to the enzyme, resulting in K_i values that were too high. However, calculations of K_i from Henderson plots, which supposedly compensate for this situation (47), were not significantly different from those in Table 4 (data not shown).

Requirement for the Sulfhydryl Group. For the BoNT F inhibitors described herein, the largest contribution to binding was presumed to result from interactions between the active site zinc of the enzyme and the sulfhydryl group of cysteine. To test this hypothesis, analogues of inhibitor 37–58/Q58D-C were synthesized, where D-cysteine was replaced with D- and L-glutamine, D- and L-aspartic acid, D- and L-histidine, D-alanine, D-serine, and D-2,3-diaminopropanoic acid. None were effective inhibitors ($K_i > 0.1$ mM). Therefore, we concluded that the sulfhydryl group of cysteine, which is most advantageously positioned in the D-isomer, probably binds to the BoNT F active site zinc, and this is responsible for much of the binding affinity.

Specificity of BoNT F Inhibition. BoNT D cleaves VAMP between residues K59 and L60, immediately C-terminal to the BoNT F cleavage site (1). BoNT D will also cleave VAMP peptide 37–75 (33). Therefore, an indication of specificity for BoNT F was determined by testing a BoNT F inhibitor against BoNT D, with peptide 37–75 as the substrate. Inhibitor 37–58/Q58D-C had a K_i value of 21 ± 3.0 μ M when BoNT D was the test enzyme, 75-fold higher than the K_i for this inhibitor against BoNT F (Table 4). When the same peptide was tested against BoNT A and BoNT B,

Table 5: Effects of Amino Acid Substitutions on Cleavability of Substrates for BoNTs A, B, E, and F^a

BoNT serotype	P_3	P_2	P_1	P_1'	P_2'	P_3'	refs
A	A	N	Q	R	A	T	31, 48
B	A	S	Q	F	E	T	29
E	I	D	R	I	M	E	48
F	R	D	Q	K	L	S	this work

^a Bold residues: no substitutions or very limited substitutions tolerated. Italic residues: substitutions tolerated. Lightface residues: not determined.

no inhibition was observed at concentrations up to 50 μ M. It is reasonable to expect that a similar pattern would be found with the other BoNT F inhibitors in Table 4. In sum, the data suggested that the inhibitors described in this work exhibit a high degree of specificity for BoNT F, compared to other BoNT serotypes.

DISCUSSION

The BoNT F substrate peptide, VAMP 37–75 in Table 1, includes both of the SNARE motifs in VAMP, residues 39–47 (V1) and 63–71 (V2). In earlier work, Pellizzari et al. (27) studied the ability of BoNT F to cleave whole recombinant VAMP containing mutations in V1 or V2. Replacing any of the acidic residues in V1 with the corresponding amide eliminated hydrolysis by BoNT F. Analogous changes in V2 diminished but did not abolish BoNT F-catalyzed cleavage. The authors concluded that the carboxylates of V1 are major substrate recognition factors for BoNT F, while those of V2 are important, but to a lesser degree. In this work, we found that VAMP peptide 42–75, which does not contain the first three residues of V1, was not hydrolyzed by BoNT F, confirming the importance of these residues for substrate function. We then determined the minimum substrate for efficient BoNT F catalysis to be the 34-amino acid peptide, VAMP 32–65 (Table 1). This substrate includes the V1 SNARE motif, but only the first two residues of V2 are present. Therefore, the complete second motif cannot be required for substrate recognition and cleavage by BoNT F. Finally, the 2-fold decrease in K_m and the 3-fold increase in V_{max} afforded by the addition of residues 32–36 to the substrate suggest that, although they are not part of any SNARE motif, these residues are important not only for binding of the substrate to BoNT F but also for efficient catalysis.

Peptide 32–65 is almost identical in size to the minimum substrate for BoNT B, VAMP 60–94 (29), but longer than the 16-residue BoNT A substrate, SNAP 25 187–202 (31). In the BoNT F minimum substrate, 27 of the required residues are on the N-terminal side of the scissile bond, while only seven are needed on the C-terminal side. The latter situation is similar to that of the BoNT A substrate, with only five residues C-terminal to the cleavage site (31), but differs from that of BoNT B, where 18 residues are needed (29).

Studies on BoNT F substrate analogues that contained substituted residues revealed important similarities and differences, compared to the enzymatic properties of BoNTs A, B, and E, with regard to residue requirements near the scissile bond. For clarity, these characteristics are summarized in Table 5. For each of the four serotypes in Table

5, the most striking feature is a strict requirement for the P_1' residue: arginine or tyrosine is required by BoNT A (31, 48), phenylalanine or tyrosine by BoNT B (29), isoleucine or valine by BoNT E (48), and lysine by BoNT F (this work). This observation is significant because it suggests that the properties of clostridial neurotoxin S_1' binding pockets are one of the most important determinants of substrate specificity for these proteinases.

In addition to stringent P_1' specificities, BoNTs A and F exhibited strong requirements for their respective P_2 residues. Peptides containing conservative replacements at this site, such as glutamine for asparagine in the BoNT A substrate (31) or glutamate for aspartate in the F substrate (Table 2), could not be hydrolyzed by the respective serotypes. Therefore, we concluded that the S_2 binding pockets on BoNTs A and F are probably well-defined and are major contributors to substrate specificities for these two serotypes.

Because glutamine is the P_1 residue in substrates for BoNTs A, B, and F and TeNT, a requirement for this particular residue at that location might be implied. Nonetheless, it could be replaced without a loss of function in substrates for the three BoNT serotypes (refs 29 and 31 and this work). Similarly, analogues containing P_3 and P_3' replacements were hydrolyzed by BoNTs A, B, and F. Changes at P_2' could be made in BoNT A and B substrates, but not in the F substrate. Taken together, the data indicated that aspartic acid at P_2 , lysine at P_1' , and leucine at P_2' are critically important for BoNT F substrate recognition near the cleavage site, while arginine at P_3 , glutamine at P_1 , and serine at P_3' are less significant.

Earlier studies reported that many nonhydrolyzable substrate analogues are weak inhibitors of BoNTs A and B, indicating that the substitutions resulted in greatly diminished binding affinities (29, 31). Loss of binding was especially pronounced when arginine at P_1' was changed in the BoNT A substrate. Although peptides containing P_2 and P_1' substitutions were not cleaved by BoNT F, they bound to this enzyme with affinities similar to those of the native sequence substrates. On the basis of these findings, we concluded that for BoNT F, substrate discrimination near the cleavage site occurs mainly at the catalytic stage and to a lesser degree at the initial binding stage.

This report is the first to describe specific and highly potent inhibitors of BoNT F protease activity. The inhibitors were obtained by substituting cysteine, an amino acid containing a potential zinc ligand, for the native sequence glutamine 58 at P_1 . Binding affinity was considerably higher when D-cysteine was present, compared to the L-isomer. Furthermore, strong binding to BoNT F required the presence of inhibitor residues on the N-terminal side of the D-cysteine at P_1 , while including residues on the C-terminal side actually diminished the affinity. Apparently, adding the latter amino acids increased the entropy of the inhibitor without a significant increase in binding strength. This situation is the opposite of that for BoNT A inhibitors, where residues C-terminal to the zinc ligand, but not N-terminal, are required (35, 36). Similar results were described for inhibitors of tetanus toxin (44, 45) and for the high-affinity pseudotriptide inhibitors of BoNT B (42), all of which are thought to occupy the S_1 , S_1' , and S_2' binding subsites on the toxins. Indeed, a requirement for inhibitor binding on the C-terminal side of the zinc ligand is a common feature among zinc

metalloproteases. Examples include thermolysin (49), angiotensin-converting enzyme (49, 50), gelatinase A (51), human neutrophil collagenase (52), and matrix metalloproteinase 2 (53). Therefore, the BoNT F requirement for N-terminal inhibitor binding moieties stands in marked contrast to the binding properties of other zinc metalloproteases.

Residue replacement experiments showed that inhibition of BoNT F required the cysteine sulfhydryl group, which presumably binds to the BoNT F active site zinc. Furthermore, the D-configuration exhibited maximum affinity. D-Cysteine alone is a strong inhibitor of bovine carboxypeptidase A, binding to the active site zinc through a sulfur ligand (54). D-Cysteine was a weak inhibitor of BoNT F [$K_i > 0.5$ mM (data not shown)], and additional amino acids were needed (VAMP residues 22–57) for optimum inhibitor positioning in the BoNT F active site. Enhanced binding afforded by these residues is unlikely to be due to the presence of any secondary structure in the inhibitor before binding to BoNT F, because whole uncomplexed VAMP in solution is mostly random coil (55).

The best inhibitors of BoNT F exhibited very strong binding, with K_i values of 1–2 nM (Table 4). Because assays contained excess zinc, these effects were not due to simple chelation of active site zinc by the sulfhydryl group. Furthermore, inhibition was highly specific for BoNT F, compared to that for BoNTs A, B, and D. Tests against other zinc metalloproteases such as thermolysin have not yet been carried out, but strong inhibition is not expected because the most effective BoNT F inhibitors have no binding groups C-terminal to the zinc ligand.

In summary, we have defined the binding and catalytic requirements of BoNT F near the cleavage site by synthesizing and testing substrate analogues. On the basis of these findings and earlier work with other serotypes, we designed and synthesized the first specific, extremely potent inhibitors of BoNT F protease activity. Furthermore, among zinc metalloendoproteases described to date, the results presented herein indicated that BoNT F is unique with respect to its requirement for inhibitor-binding groups on the N-terminal side of the zinc ligand. Finally, the substrate and inhibitor characteristics described in this report suggest that BoNT F will have fewer highly structured binding subsites C-terminal to the hydrolysis site, compared to the N-terminal side.

ACKNOWLEDGMENT

The research described herein was conducted under research plan 02-4-3U-063. Opinions, interpretations, conclusions, and recommendations are those of the authors and are not necessarily endorsed by the U.S. Army. We thank Mr. Ernst Brueggemann and Dr. Harry Hines for analyses of peptides by mass spectrometry and Dr. Frank Lebeda for helpful review of the manuscript.

REFERENCES

1. Schiavo, G., Matteoli, M., and Montecucco, C. (2000) Neurotoxins affecting neuroexocytosis, *Physiol. Rev.* 80, 717–766.
2. Harvey, S. M., Sturgeon, J., and Dassey, D. E. (2002) Botulism due to *Clostridium baratii* type F toxin. *J. Clin. Microbiol.* 40, 2260–2262.
3. Fenicia, L., Franciosa, G., Pourshaban, M., and Aureli, P. (1999) Intestinal toxemia botulism in two young people, caused by *Clostridium butyricum* type E, *Clin. Infect. Dis.* 29, 1381–1387.

4. Singh, B. R. (2000) Intimate details of the most poisonous poison, *Nat. Struct. Biol.* 7, 617–619.
5. Kalluri, P., Crowe, C., Reller, M., Gaul, L., Hayslett, J., Barth, S., Eliasberg, S., Ferreira, J., Holt, K., Bengston, S., Hendricks, K., and Sobel, J. (2003) An outbreak of foodborne botulism associated with food sold at a salvage store in Texas, *Clin. Infect. Dis.* 37, 1490–1495.
6. Werner, S. B., Passaro, D., McGee, J., Schechter, R., and Vugia, D. J. (2000) Wound botulism in California, 1951–1998: Recent epidemic in heroin users, *Clin. Infect. Dis.* 31, 1018–1024.
7. Barash, J. R., and Arnon, S. S. (2004) Dual toxin-producing strain of *Clostridium botulinum* type Bf isolated from a California patient with infant botulism, *J. Clin. Microbiol.* 42, 1713–1715.
8. Nieman, H., Blasi, J., and Jahn, R. (1994) Clostridial neurotoxins: New tools for dissecting exocytosis, *Trends Cell Biol.* 5, 179–185.
9. Schiavo, G., Rossetto, O., and Montecucco, C. (1994) Clostridial neurotoxins as tools to investigate the molecular events of neurotransmitter release, *Semin. Cell Biol.* 4, 221–229.
10. Pellizzari, R., Rossetto, O., Schiavo, G., and Montecucco, C. (1999) Tetanus and botulinum neurotoxins: Mechanism of action and therapeutic uses, *Philos. Trans. R. Soc. London* 354, 259–268.
11. Rossetto, O., Seveso, M., Caccin, P., Schiavo, G., and Montecucco, C. (2001) Tetanus and botulinum neurotoxins: Turning bad guys into good by research, *Toxicon* 39, 27–41.
12. Turton, K., Chaddock, J. A., and Acharya, K. R. (2002) Botulinum and tetanus neurotoxins: Structure, function, and therapeutic utility, *Trends Biochem. Sci.* 27, 552–558.
13. Cherington, M. (2004) Botulism: Update and review, *Semin. Neurol.* 24, 155–163.
14. Arnon, S. S., Schechter, R., Inglesby, T. V., Henderson, D. A., Bartlett, J. G., Ascher, M. S., Eitzen, E., Fine, A. D., Hauer, J., Layton, M., Lillibridge, S., Osterholm, M. T., O'Toole, T., Parker, G., Russel, P. K., Swerdlow, D. L., and Tonat, K. (2001) Botulinum toxin as a biological weapon, *J. Am. Med. Assoc.* 285, 1059–1070.
15. Simpson, L. L. (2004) Identification of the major steps in botulinum toxin action, *Annu. Rev. Pharmacol. Toxicol.* 44, 167–193.
16. Koriazova, L. K., and Montal, M. (2003) Translocation of botulinum neurotoxin light chain protease through the heavy chain channel, *Nat. Struct. Biol.* 10, 13–18.
17. Maksymowych, A. B., and Simpson, L. L. (1998) Binding and transcytosis of botulinum neurotoxin by polarized human colon carcinoma cells, *J. Biol. Chem.* 273, 21950–21957.
18. Byrne, M. P., and Smith, L. A. (2000) Development of vaccines for prevention of botulism, *Biochimie* 82, 955–966.
19. Shi, Y. L., and Wang, Z. F. (2004) Cure of experimental botulism and antibotulismic effect of toosendanin, *Acta Pharmacol. Sin.* 25, 839–848.
20. Keller, J. E., Cai, F., and Neale, E. A. (2004) Uptake of botulinum neurotoxin into cultured neurons, *Biochemistry* 43, 526–532.
21. Foran, P., Shone, C. C., and Dolly, J. O. (1994) Differences in the protease activities of tetanus and botulinum B toxins revealed by the cleavage of vesicle-associated membrane protein and various sized fragments, *Biochemistry* 33, 15365–15374.
22. Deshpande, S. S., Sheridan, R. E., and Adler, M. (1995) A study of zinc-dependent metalloproteinase inhibitors as pharmacologic antagonists in botulinum neurotoxin poisoning, *Toxicon* 33, 551–557.
23. Adler, M., Nicholson, J. D., Starks, D. F., Kane, C. T., Cornille, F., and Hackley, B. E. (1999) Evaluation of phosphoramidon and three synthetic phosphonates for inhibition of botulinum neurotoxin B catalytic activity, *J. Appl. Toxicol.* 19, S5–S11.
24. Adler, M., Dinterman, R. E., and Wannemacher, R. W. (1997) Protection by the heavy metal chelator N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine (TPEN) against the lethal action of botulinum neurotoxin A and B, *Toxicon* 35, 1089–1100.
25. Humeau, Y., Doussau, F., Grant, N., and Poulain, B. (2000) How botulinum and tetanus neurotoxins block neurotransmitter release, *Biochimie* 82, 427–446.
26. Rossetto, O., Schiavo, G., Montecucco, C., Poulaun, B., Deloye, F., Lozzl, L., and Shone, C. C. (1994) SNARE motif and neurotoxins, *Nature* 372, 415–416.
27. Pellizzari, R., Mason, S., Shone, C., and Montecucco, C. (1997) The interaction of synaptic vesicle-associated membrane protein/synaptobrevin with botulinum neurotoxins D and F, *FEBS Lett.* 409, 339–342.
28. Shone, C. C., Quinn, C. P., Wait, R., Hallis, B., Fooks, S. G., and Hambleton, P. (1993) Proteolytic cleavage of synthetic fragments of vesicle-associated membrane protein, isoform-2 by botulinum type B neurotoxin, *Eur. J. Biochem.* 217, 965–971.
29. Shone, C. C., and Roberts, A. K. (1994) Peptide substrate specificity and properties of the zinc-endopeptidase activity of botulinum type B neurotoxin, *Eur. J. Biochem.* 225, 263–270.
30. Schmidt, J. J., and Bostian, K. A. (1995) Proteolysis of synthetic peptides by type A botulinum neurotoxin, *J. Protein Chem.* 14, 703–708.
31. Schmidt, J. J., and Bostian, K. A. (1997) Endoprotease activity of type A botulinum neurotoxin: Substrate requirements and activation by serum albumin, *J. Protein Chem.* 16, 19–26.
32. Anne, C., Cornille, F., Lenoir, C., and Roques, B. P. (2001) High-throughput fluorogenic assay for determination of botulinum type B neurotoxin protease activity, *Anal. Biochem.* 291, 253–261.
33. Schmidt, J. J., Stafford, R. G., and Millard, C. B. (2001) High-throughput assays for botulinum neurotoxin proteolytic activity: Serotypes A, B, D, and F, *Anal. Biochem.* 296, 130–137.
34. Schmidt, J. J., and Stafford, R. G. (2003) Fluorogenic substrates for the protease activities of botulinum neurotoxins, serotypes A, B, and F, *Appl. Environ. Microbiol.* 69, 297–303.
35. Schmidt, J. J., Stafford, R. G., and Bostian, K. A. (1998) Type A botulinum neurotoxin proteolytic activity: Development of competitive inhibitors and implications for substrate specificity at the S₁' binding subsite, *FEBS Lett.* 435, 61–64.
36. Schmidt, J. J., and Stafford, R. G. (2002) A high-affinity competitive inhibitor of type A botulinum neurotoxin A metalloprotease activity, *FEBS Lett.* 532, 423–426.
37. Burnett, J. C., Schmidt, J. J., Stafford, R. G., Panchal, R. G., Nguyen, T. L., Hermone, A. R., Vennerstrom, J. L., McGrath, C. F., Lane, D. J., Sausville, E. A., Zaharevitz, D. W., Gussio, R., and Bavari, S. (2003) Novel small molecule inhibitors of botulinum neurotoxin protease activity, *Biochem. Biophys. Res. Commun.* 310, 85–94.
38. Sukonpan, C., Oost, T., Goodnough, M., Tepp, W., Johnson, E. A., and Rich, D. H. (2004) Synthesis of substrates and inhibitors of botulinum neurotoxin type A metalloprotease, *J. Pept. Res.* 63, 181–193.
39. Adler, M., Nicholson, J. D., and Hackley, B. E. (1998) Efficacy of a novel metalloprotease inhibitor on botulinum neurotoxin B activity, *FEBS Lett.* 429, 234–238.
40. Garcia, G. E., Moorad, D. R., and Gordon, R. K. (1999) Buforin I, a natural peptide, inhibits botulinum neurotoxin B activity *in vitro*, *J. Appl. Toxicol.* 19, S19–S22.
41. Eswaramoorthy, S., Kumaran, D., and Swaminathan, S. (2002) A novel mechanism for *Clostridium botulinum* neurotoxin inhibition, *Biochemistry* 41, 9795–9802.
42. Blommaert, A., Turcaud, S., Anne, C., and Roques, B. P. (2004) Small tripeptide surrogates with low nanomolar affinity as potent inhibitors of the botulinum neurotoxin B metalloprotease activity, *Bioorg. Med. Chem.* 12, 3055–3062.
43. Oost, T., Sukonpan, C., Brewer, M., Goodnough, M., Tepp, W., Johnson, E. A., and Rich, D. H. (2003) Design and synthesis of substrate-based inhibitors of botulinum neurotoxin type B metalloprotease, *Biopolymers* 71, 602–619.
44. Martin, L., Cornille, F., Coric, P., Roques, B. P., and Fournie-Zaluskie, M. C. (1998) β -Amino thiols inhibit the zinc metalloprotease activity of tetanus toxin light chain, *J. Med. Chem.* 41, 3450–3460.
45. Martin, L., Cornille, F., Turcaud, S., Meudal, H., Roques, B. P., and Fournie-Zaluskie, M. C. (1999) Metalloprotease inhibitors of tetanus toxin: A combinatorial approach, *J. Med. Chem.* 42, 515–525.
46. Segel, I. H. (1975) *Enzyme kinetics*, pp 109–111, Wiley, New York.
47. Henderson, P. J. (1972) A linear equation that describes the steady-state kinetics of enzymes and subcellular particles interacting with tightly bound inhibitors, *Biochem. J.* 127, 321–333.
48. Vadakkanchery, V. V., Yoshino, K., Jahnz, M., Dürries, C., Bade, S., Nauenberg, S., Nieman, H., and Binz, T. (1999) Proteolysis of SNAP-25 isoforms by botulinum neurotoxin types A, C, and E: Domains and amino acid residues controlling the formation of enzyme–substrate complexes and cleavage, *J. Neurochem.* 72, 327–337.
49. Bohacek, R., De Lombaert, S., McMartin, C., Priestle, J., and Grütter, M. (1996) Three-dimensional models of ACE and NEP

- inhibitors and their use in the design of potent dual ACE/NEP inhibitors, *J. Am. Chem. Soc.* 118, 8231–8249.
50. Natesh, R., Schwager, S. L., Sturrock, E. D., and Acharya, K. R. (2003) Crystal structure of the human angiotensin-converting enzyme-lisinopril complex, *Nature* 421, 551–554.
51. Auge, F., Hornebeck, W., and Laronze, J. Y. (2004) A novel strategy for designing specific gelatinase A inhibitors: Potential use to control tumor progression, *Crit. Rev. Oncol. Hematol.* 49, 277–282.
52. Betz, M., Huxley, P., Davies, S. J., Mushtaq, Y., Pieper, M., Tschesche, H., Bode, W., and Gomis-Rüth, F. X. (1997) 1.8-Å crystal structure of the catalytic domain of human neutrophil collagenase (matrix metalloproteinase-8) complexed with a peptidomimetic hydroxamate primed-side inhibitor with a distinct selectivity profile, *Eur. J. Biochem.* 247, 356–363.
53. Rosenblum, G., Meroueh, S. O., Kleifeld, O., Brown, S., Singson, S. P., Fridman, R., Mobashery, S., and Sagit, I. (2003) Structural basis for potent slow binding inhibition of human matrix metalloproteinase-2 (MMP-2), *J. Biol. Chem.* 278, 27009–27015.
54. van Alten, D. M., Chong, C. R., and Joshua-Tor, L. (2000) Crystal structure of carboxypeptidase A complexed with D-cysteine at 1.75 Å: Inhibitor-induced conformational changes, *Biochemistry* 39, 10082–10089.
55. Cornille, F., Goudreau, N., Ficheux, D., Nieman, H., and Roques, B. P. (1994) Solid-phase synthesis, conformational analysis and *in vitro* cleavage of synthetic human synaptobrevin II 1–93 by tetanus toxin L chain, *Eur. J. Biochem.* 222, 173–181.

BI0477642